Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

CRF: Circulating recombinant form; NNRTI: Non-nucleoside reverse-transcriptase inhibitor; NRTI: Nucleos(t)ide analog reverse-transcriptase inhibitor. Eight nucleos(t)ide analog reverse ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Researchers at The University of Texas MD Anderson Cancer Center have made a groundbreaking discovery in the fight against ...

It is an ester-derived prodrug that is converted in vivo by serum and tissue esterases to tenofovir, an acyclic nucleoside phosphonate (nucleotide) that inhibits HIV reverse transcriptase.

The following is a summary of “High-density lipoprotein anti-inflammatory capacity and acute kidney injury after cardiac and ...

“This is an important milestone for Life Edit as we advance our proprietary delivery platforms alongside our base and reverse transcriptase editing capabilities to develop and deliver safe and ...

Non-nucleoside reverse transcriptase inhibitor + reverse transcriptase inhibitors (nucleoside + nucleotide analogue). Efavirenz activity is mediated predominantly by noncompetitive inhibition of ...